Cara Cassino, MD

Chief Medical Officer and Executive Vice President of Research and Development
ContraFect Corporation
Yonkers, NY

Disclosure: ContraFect Corporation: Employee

Presentation(s):

• LB3 - Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study

  Thursday, October 3
  2:05 PM – 2:15 PM